Advertisement

Pituitary

, Volume 22, Issue 6, pp 569–573 | Cite as

A tale of pituitary adenomas: to NET or not to NET

Pituitary Society position statement
  • Ken K. Y. HoEmail author
  • Maria Fleseriu
  • John Wass
  • Aart van der Lely
  • Ariel Barkan
  • Andrea Giustina
  • Felipe F. Casanueva
  • Anthony P. Heaney
  • Nienke Biermasz
  • Christian Strasburger
  • Shlomo Melmed
Article

Current and proposed change of classification

Anterior pituitary tumors arising from oral ectoderm-derived differentiated hormone-expressing lineages are classified according to cell type, size, location, secretory function and neoplastic behavior. The pathological classification of pituitary tumors has been driven by advances in physiology, cell biology and genetics. Almost all pituitary adenomas are benign neoplasms; extremely rarely, some may undergo malignant transformation, metastasizing to extracranial sites. An intermediate group of higher risk locally invasive adenomas are described as ‘atypical’ or ‘aggressive’ based on clinical features.

In the 2004 Classification of Endocrine Tumors, the World Health Organization (WHO) defined this latter group as atypical pituitary adenomas while retaining previous functional classification based on hormone immunohistochemistry [1]. A modification to the classification of pituitary adenomas was proposed in 2017 [2]. WHO recommended that...

Keywords

Pituitary adenoma Neuroendocrine tumor Tumor classification 

Notes

Acknowledgements

This position paper is co-authored by the Editors of PITUITARY and Officers of the Pituitary Society. No external or Society funding supported this work. The authors thank Shira Berman for outstanding editorial assistance.

References

  1. 1.
    WHO (2004) Pathology and genetics of tumours of endocrine organs. WHO classification of tumours, vol 8, 3 edn. WHO Press, GenevaGoogle Scholar
  2. 2.
    WHO (2017) WHO classification of tumours of endocrine organs. WHO classification of tumours, vol 10, 4 edn. WHO Press, GenevaGoogle Scholar
  3. 3.
    Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER Jr, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A, Villa C, Wierinckx A, Trouillas J (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 24(4):C5–c8.  https://doi.org/10.1530/erc-17-0004 CrossRefGoogle Scholar
  4. 4.
    Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Kloppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) Expert Consensus proposal. Mod Pathol 31(12):1770–1786.  https://doi.org/10.1038/s41379-018-0110-y CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Solcia E, Kloppel G, Sobin LH (2000) Histological typing of endocrine tumours. World Health Organization international histological classification of tumours, 2nd edn. Springer, BerlinCrossRefGoogle Scholar
  6. 6.
    Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25(3):458–511.  https://doi.org/10.1210/er.2003-0014 CrossRefPubMedGoogle Scholar
  7. 7.
    Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317(5):516–524.  https://doi.org/10.1001/jama.2016.19699 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chambers EF, Turski PA, LaMasters D, Newton TH (1982) Regions of low density in the contrast-enhanced pituitary gland: normal and pathologic processes. Radiology 144(1):109–113.  https://doi.org/10.1148/radiology.144.1.7089241 CrossRefPubMedGoogle Scholar
  9. 9.
    Wolpert SM, Molitch ME, Goldman JA, Wood JB (1984) Size, shape, and appearance of the normal female pituitary gland. Am J Roentgenol 143(2):377–381.  https://doi.org/10.2214/ajr.143.2.377 CrossRefGoogle Scholar
  10. 10.
    Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH (1994) Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120(10):817–820.  https://doi.org/10.7326/0003-4819-120-10-199405150-00001 CrossRefPubMedGoogle Scholar
  11. 11.
    Chong BW, Kucharczyk W, Singer W, George S (1994) Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas. Am J Neuroradiol 15(4):675–679PubMedGoogle Scholar
  12. 12.
    Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the Province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769–4775.  https://doi.org/10.1210/jc.2006-1668 CrossRefPubMedGoogle Scholar
  13. 13.
    Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377–382.  https://doi.org/10.1111/j.1365-2265.2009.03667.x CrossRefGoogle Scholar
  14. 14.
    Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol 173(5):655–664.  https://doi.org/10.1530/eje-15-0189 CrossRefPubMedGoogle Scholar
  15. 15.
    Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114(2):336–344.  https://doi.org/10.3171/2010.8.Jns10290 CrossRefPubMedGoogle Scholar
  16. 16.
    Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young Jr WF, Meyer FB, Kuroki T, Riehle DL, Laws Jr ER (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59(2):341–353; discussion 341–353.  https://doi.org/10.1227/01.Neu.0000223437.51435.6e CrossRefGoogle Scholar
  17. 17.
    Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216.  https://doi.org/10.1530/eje.1.02326 CrossRefPubMedGoogle Scholar
  18. 18.
    Yildirim AE, Divanlioglu D, Nacar OA, Dursun E, Sahinoglu M, Unal T, Belen AD (2013) Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas. Turk Neurosurg 23(2):226–231.  https://doi.org/10.5137/1019-5149.Jtn.6828-12.1 CrossRefPubMedGoogle Scholar
  19. 19.
    Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, de Waure C, Lauriola L, Mangiola A, Anile C, Maira G, De Marinis L, Bianchi A (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101(2):143–150.  https://doi.org/10.1159/000375448 CrossRefPubMedGoogle Scholar
  20. 20.
    Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7(5):257–266.  https://doi.org/10.1038/nrendo.2011.40 CrossRefPubMedGoogle Scholar
  21. 21.
    Raverot G, Jouanneau E, Trouillas J (2014) Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol 170(4):R121–R132.  https://doi.org/10.1530/eje-13-1031 CrossRefPubMedGoogle Scholar
  22. 22.
    Nasi D, Perano D, Ghadirpour R, Iaccarino C, Servadei F, Romano A (2017) Primary pituitary neuroendocrine tumor: case report and literature review. Surg Neurol Int 8:101.  https://doi.org/10.4103/sni.sni_450_16 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Liu H, Wang H, Qi X, Yu C (2016) Primary intracranial neuroendocrine tumor: two case reports. World J Surg Oncol 14:138.  https://doi.org/10.1186/s12957-016-0887-4 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Marx SJ, Nieman LK (2002) Aggressive pituitary tumors in MEN1: do they refute the two-hit model of tumorigenesis? J Clin Endocrinol Metab 87(2):453–456.  https://doi.org/10.1210/jcem.87.2.8289 CrossRefPubMedGoogle Scholar
  25. 25.
    Satoh F, Umemura S, Yasuda M, Osamura RY (2001) Neuroendocrine marker expression in thyroid epithelial tumors. Endocr Pathol 12(3):291–299CrossRefGoogle Scholar
  26. 26.
    Haak HR, Fleuren GJ (1995) Neuroendocrine differentiation of adrenocortical tumors. Cancer 75(3):860–864.  https://doi.org/10.1002/1097-0142(19950201)75:3%3c860:aid-cncr2820750318%3e3.0.co;2-g CrossRefPubMedGoogle Scholar
  27. 27.
    Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society statement. Pituitary 20(5):489–498.  https://doi.org/10.1007/s11102-017-0838-2 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ken K. Y. Ho
    • 1
    Email author
  • Maria Fleseriu
    • 2
  • John Wass
    • 3
  • Aart van der Lely
    • 4
  • Ariel Barkan
    • 5
  • Andrea Giustina
    • 6
  • Felipe F. Casanueva
    • 7
  • Anthony P. Heaney
    • 8
  • Nienke Biermasz
    • 9
  • Christian Strasburger
    • 10
  • Shlomo Melmed
    • 11
  1. 1.The Garvan Institute of Medical Research, St. Vincents HospitalThe University of New South WalesSydneyAustralia
  2. 2.Departments of Medicine and Neurological Surgery, Pituitary CenterOregon Health & Science UniversityPortlandUSA
  3. 3.Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and MetabolismChurchill HospitalOxfordUK
  4. 4.Pituitary Center Rotterdam, Endocrinology Section, Department of Internal MedicineErasmus University Medical CenterRotterdamThe Netherlands
  5. 5.Division of EndocrinologyUniversity of Michigan Health SystemAnn ArborUSA
  6. 6.Division of Endocrinology and MetabolismSan Raffaele University HospitalMilanItaly
  7. 7.Division of EndocrinologySantiago de Compostela University and Ciber OBNSantiagoSpain
  8. 8.Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, David Geffen School of MedicineUniversity of CaliforniaLos AngelesUSA
  9. 9.Division of Endocrinology and Center for Endocrine Tumors, Department of MedicineLeiden University Medical CenterLeidenThe Netherlands
  10. 10.Department of Medicine for Endocrinology, Diabetes and Nutritional MedicineCharité UniversitätsmedizinBerlinGermany
  11. 11.Pituitary Center, Department of MedicineCedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations